Multiple genetic factors affecting the pharmacokinetic and pharmacodynamic processes of tacrolimus in Chinese myasthenia gravis patients
Author:
Funder
National Natural Science Foundation of China
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,General Medicine
Link
http://link.springer.com/content/pdf/10.1007/s00228-019-02803-0.pdf
Reference29 articles.
1. Cao Y, Lu X, Wang J, Zhang H, Liu Z, Xu S, Wang T, Ning S, Xiao B, Wang L (2017) Construction of an miRNA-regulated drug-pathway network reveals drug repurposing candidates for myasthenia gravis. Int J Mol Med 39(2):268–278
2. Tao X, Wang W, Jing F, Wang Z, Chen Y, Wei D, Huang X (2017) Long-term efficacy and side effects of low-dose tacrolimus for the treatment of myasthenia gravis. Neurol Sci 38(2):325–330
3. Cruz JL, Wolff ML, Vanderman AJ, Brown JN (2015) The emerging role of tacrolimus in myasthenia gravis. Ther Adv Neurol Disord 8(2):92–103
4. Liu C, Gui M, Cao Y, Lin J, Li Y, Ji S, Bu B (2017) Tacrolimus improves symptoms of children with myasthenia gravis refractory to prednisone. Pediatr Neurol 77:42–47
5. Zhao CB, Zhang X, Zhang H, Hu XQ, Lu JH, Lu CZ, Xiao BG (2011) Clinical efficacy and immunological impact of tacrolimus in Chinese patients with generalized myasthenia gravis. Int Immunopharmacol 11(4):519–524
Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Non-coding RNA and its network in the pathogenesis of Myasthenia Gravis;Frontiers in Molecular Biosciences;2024-09-10
2. SNPs in 3′UTR miRNA Target Sequences Associated with Individual Drug Susceptibility;International Journal of Molecular Sciences;2022-11-08
3. miR-181a Ameliorates the Progression of Myasthenia Gravis by Regulating TRIM9;Evidence-Based Complementary and Alternative Medicine;2021-12-09
4. Tacrolimus as Single-Agent Immunotherapy and Minimal Manifestation Status in Nonthymoma Myasthenia Gravis;Journal of Immunology Research;2021-11-20
5. Clinical Evaluation of the Efficacy and Safety of Co-Administration of Wuzhi Capsule and Tacrolimus in Adult Chinese Patients with Myasthenia Gravis;Neuropsychiatric Disease and Treatment;2021-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3